Author:
King Daniel A,Smith Amber R,Pineda Gino,Nakano Michitaka,Michelini Flavia,Goedegebuure S. Peter,Thyparambil Sheeno,Liao Wei-Li,McCormick Aaron,Ju Jihang,Cioffi Michele,Zhang Xiuli,Hundal Jasreet,Griffith Malachi,Grandori Carla,Pollastro Maddy,Rosati Rachele,Margossian Astrid,Chatterjee Payel,Ainge Trevor,Flory Marta,Ocampo Paolo,Chen Lee-may,Poultsides George A,Baron Ari D,Chang Daniel T,Herman Joseph M,Gillanders William E,Park Haeseong,Hoos William A,Nichols Mike,Fisher George A,Kuo Calvin J
Abstract
AbstractHere, we demonstrate a complete clinical response achieved in a patient with HER2+ metastatic pancreatic ductal adenocarcinoma to a coordinated barrage of anti-HER2, personalized vaccine and checkpoint inhibition immunotherapy, radiation, and chemotherapy. Comprehensive organoid profiling with drug sensitivity screening and drug testing suggested a vulnerability to anti-HER2 directed therapy, facilitating personalized treatment selection for our patient, which contributed to her clinical benefit. Immune response monitoring following personalized vaccine, radiation and checkpoint inhibition showed a sustained increase in neoantigen specific T cell response.
Publisher
Cold Spring Harbor Laboratory